Zhiyong Yu

The Neglected Role of GSDMD C‐Terminal in Counteracting Type I Interferon Signaling

Pyrotinib in the first-line treatment of HER2-positive advanced breast cancer: Results from the PRETTY study.

Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer

Real‐world treatment patterns and outcomes of pyrotinib‐based therapy in patients with <scp>HER2</scp>‐positive advanced breast cancer (<scp>PRETTY</scp>): A nationwide, prospective, observational study

Spatial immunophenotypes orchestrate prognosis in triple-negative breast cancer with Miller-Payne grade 4 following neoadjuvant chemotherapy

Pivotal roles of tumor‐draining lymph nodes in the abscopal effects from combined immunotherapy and radiotherapy

Abstract P2-13-40: Treatment patterns and adverse events of pyrotinib-based therapy in HER2-positive breast cancer patients in China: Results from a multicenter, real-world study

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Prophylactic transcatheter arterial embolization for high-risk ulcers following endoscopic hemostasis: a meta-analysis

ELF3‐AS1 contributes to gastric cancer progression by binding to hnRNPK and induces thrombocytosis in peripheral blood

&lt;p&gt;EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling&lt;/p&gt;

A novel long noncoding RNA, TMEM92‐AS1, promotes gastric cancer progression by binding to YBX1 to mediate CCL5

Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters

LncRNA NEF is downregulated in triple negative breast cancer and correlated with poor prognosis

Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer